Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis

J Clin Neuromuscul Dis. 2018 Dec;20(2):49-59. doi: 10.1097/CND.0000000000000219.

Abstract

Objectives: To estimate the satisfactory response rate (SR%) with achieving maintenance, low-dose prednisone in acetylcholine receptor antibody-positive generalized myasthenia gravis.

Methods: In this retrospective study, we estimate the SR% as defined by (remission/minimal manifestations status for at least 6 months using 7.5 mg or less of prednisone daily, for maintenance treatment at 2, 4, and 6 years after symptoms onset) for patients who were not taking steroid-sparing immunosuppressant (SSI) as a primary outcome and for patients taking an SSI as a secondary outcome.

Results: Forty-five patients were not taking an SSI at 2 years, 34 patients at 4 years, and 17 patients at 6 years; SR% was 44.4%, 64.7%, and 58.8%, respectively. Thirty-six patients were taking an SSI at 2 years, 22 patients at 4 years, and 15 patients at 6 years; the SR% was 50.0%, 45.4%, and 66.7%, respectively.

Conclusions: Nearly half of the generalized myasthenia gravis patients who were not taking an SSI achieved an SR.

MeSH terms

  • Adult
  • Aged
  • Anti-Inflammatory Agents / therapeutic use*
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Myasthenia Gravis / drug therapy*
  • Prednisone / therapeutic use*
  • Receptors, Cholinergic / immunology
  • Retrospective Studies
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Receptors, Cholinergic
  • Prednisone